AVXL stock forecast
Our latest prediction for Anavex Life Sciences Corp.'s stock price was made on the March 7, 2018 when the stock price was at 2.89$.
In the short term (2weeks), AVXL's stock price should outperform the market by 4.54%. During that period the price should oscillate between -8.94% and +14.82%.
In the medium term (3months), AVXL's stock price should outperform the market by 5.77%. During that period the price should oscillate between -20.05% and +37.44%.Get email alerts
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.39$ per share.
The book value per share is 0.52$
Three months stock forecastMarch 7, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|